Stock comparison
BioCryst Pharmaceuticals
BCRX
Market cap
$2.14B
Sector
Healthcare
Overall winner
LeMaitre Vascular
BCRX 0–7 LMAT
LeMaitre Vascular
LMAT
Market cap
$2.16B
Sector
Healthcare
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
Fit scores by strategy
BCRXvsLMAT
40D
77B
24F
89A
40D
81C
60C
67B
4F
56D
35D
68D
41D
69D
Side-by-side metrics
| Metric | BCRX | LMAT |
|---|---|---|
| Market cap | $2.14B | $2.16B |
| P/E (TTM) | - | 37.1x |
| EV/EBIT | 7.6x | 36.6x |
| ROIC (TTM) | -121.96% | 9.43% |
| Gross margin | 18.89% | 72.39% |
| Net margin | -51.71% | 24.35% |
| Revenue CAGR 5y | 53.6% | 12.75% |
| EPS CAGR 5y | - | 19.04% |
| Debt / Equity | - | 0.5x |
| Dividend yield | 0.0% | 0.84% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
BCRX leads on
- Debt / Equity-vs 0.5x+130%
- P/E (TTM)-vs 37.1x+113%
- EV/EBIT7.6xvs 36.6x+79%
- Revenue CAGR 5y53.6%vs 12.75%+76%
LMAT leads on
- Net margin24.35%vs -51.71%+147%
- ROIC (TTM)9.43%vs -121.96%+108%
- Dividend yield0.84%vs 0.0%+100%
- Gross margin72.39%vs 18.89%+74%
More like BCRX
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.